June 6, 2022
Five studies using MicroGenDX molecular testing highlight diagnostic applications, as published in May Journal of Urology
April 21, 2022
MicroGenDX continues to expand its growth and expertise in molecular diagnostics by acquiring sampling innovator Captigen along with Captigen’s extensive inventory of flatswabs. The Captigen flatswab is a cross-platform precision microbial sampling device designed for optimized culture yield, RT-PCR yield, and next-generation sequencing (NGS).
February 22, 2022
The New York permit approval process has required compliance with rigorous operating and proficiency standards for bacteriology and mycology laboratories. The permit became effective February 17, 2022.
January 24, 2022
Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly to patients, raising awareness about much more effective DNA analysis alternatives to outdated medical diagnostic technologies like standard culture. The campaign, scheduled for February of 2022, includes testimonials from patients about how MicroGenDX diagnostics helped them – and in some cases saved their lives – when standard cultures failed.
December 14, 2021
Clinical research using MicroGenDX molecular testing highlights diagnostic applications